<DOC>
	<DOCNO>NCT01076595</DOCNO>
	<brief_summary>The aim SEPLUS study evaluate patient characteristic associated adherence Betaferon 24-month follow period initiation Betaferon BetaPlus program</brief_summary>
	<brief_title>Prospective , Multicenter Non Interventional Study Evaluate Adherence Betaferon Over 2 Years Period</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interferon-beta</mesh_term>
	<mesh_term>Interferon beta-1b</mesh_term>
	<criteria>Male female &gt; /= 18 year old Outpatient confirm diagnosis RecurrentRemittent multiple sclerosis patient high risk develop multiple sclerosis first demyelinate clinical event Patient initiate Betaferon describe SmPC le 2 month ago . The decision physician clearly separate decision include patient study Treatment na√Øve patient initiation Betaferon OR Patients interrupt Betaferon 6 month start OR Patients receive disease modify drug ( DMD ) Betaferon Patient EDSS score &lt; 4 Patients approve signed inform consent approve collect data Contraindications warn respective Summary Product Characteristics</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2015</verification_date>
	<keyword>Multiple sclerosis</keyword>
	<keyword>BetaPlus program</keyword>
	<keyword>Recurrent/remittent multiple sclerosis patient</keyword>
	<keyword>Adherence treatment regimen</keyword>
</DOC>